1640-1641 / 2063
TBI + ChT
Phase III
randomised,
placebo
controlled
Placebo
(n = 106)
Grade 4
Grade 3
Grade 3
Grade 0
Grade 2
Incidence of mucositis [%]
80
60
40
20
0
100
Grade 2
Grade 1
Palifermin (rHuKGF)
(n = 106)
day -3, -2, -1 / 1, 2, 3
Grade 4
Spielberger et al., NEJM 35, 2004, 2590-2598
Keratinocyte Growth Factor (Palifermin)
Intervention with signaling